人福医药：产品“左炔诺孕酮片”取得注册证

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval for the drug "Levonorgestrel Tablets" from the National Medical Products Administration [1] - Renfu Pharmaceutical's revenue composition for the year 2024 is as follows: 56.01% from pharmaceuticals, 43.8% from pharmaceutical wholesale and related businesses, and 0.19% from other businesses [1] - As of the report, Renfu Pharmaceutical has a market capitalization of 36.3 billion yuan [1]